ABOUT
    ABOUT US
    LEADERSHIP
        Executive Team
    MILESTONE
PRODUCT
    ALL
    Iron Deficiency Anemia
    Emergency Care
    Respiratory
PIPELINE
    PIPELINE
        Respiratory
        Pain Management
        Emergency Care
        Iron Deficiency Anemia
PARTNERSHIP
NEWS
    ALL
    Press Releases
        Strategic Cooperation Agreement with SHAPHAR
        Nuance Pharma advances Rare Disease R&D with CORD
        COPD新药 Ensifentrine 全球III期临床 ENHANCE-2 试验全解读
        优锐医药助力2022第十一届中国罕见病高峰论坛成功举办
        优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
    Media
        Nuance Pharma Closes Series D Financing
        Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
        Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
        Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
        Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
        Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
        Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
        Partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau
        IND Approval for Respiratory Syncytial Virus (RSV) Vaccine in China
        IND Approval for Ensifentrine Pivotal Clinical Trials for COPD in China
        专访优锐医药:呼吸精品特药领域,如何打造现金“造血”教科书?
        RSV疫苗中国III期临床获批,呼吸特药精耕又一里程碑!
    Partner News
        Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
        Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
        Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
        Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
        BAVARIAN NORDIC ANNOUNCES GRANT OF PRIME ELIGIBILITY FROM THE EUROPEAN MEDICINES AGENCY FOR ITS RSV VACCINE CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS IN OLDER ADULTS
        Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
        Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
INVESTOR
CAREER
    PROFILE
CONTACT